

## Information on the total number of voting rights and shares

**Mont-Saint-Guibert, Belgium, May 31, 2024, 7.00 am CEST – [BIOSENIC](#)** (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007 on the publication of major shareholdings in issuers whose shares are admitted to trading on regulated market.

Total amount of share capital on April 30, 2024	EUR 36 450 669
Total number of shares with voting rights on April 30, 2024	214 698 943
Total number of new shares issued between April 30, 2024 and May 31, 2024	16 025 640

Total amount of share capital on May 31, 2024	EUR 36 650 669
Total number of shares with voting rights on May 31, 2024	230 724 583
Total number of voting rights (denominator) on May 31, 2024	230 724 583
Total number of attributed warrants	161 556
Total number of convertible bonds outstanding	176
Total number of remaining convertible bonds commitments	0
Total number of shares with voting rights that can be issued following the exercise of the attributed warrants, remaining convertible bonds commitments and the conversion of the convertible bonds	555 351 874 <sup>(1)</sup>

(1)

- 161 556 shares could be issued in case all 161 556 attributed warrants were exercised (excluding the 1 000 000 outstanding warrants which are intended to be cancelled in accordance with the global restructuring plan which received a positive vote from BioSenic's creditors on 27 May 2024).
- 129 005 524 shares could be issued in case all 176 convertible bonds outstanding of the convertible bonds programs with Global Tech Opportunities 15 were exercised and converted into shares based on the conversion price of EUR 0.0181 (95% of the Volume-Weighted-Averaged-Price of BioSenic's shares on 29 May 2024).
- In the event of full conversion of the new convertible bonds in accordance with the global restructuring plan which received a positive vote from BioSenic's creditors on 27 May 2024, 426 184 794 shares could be issued in case all of the EUR 7.5 million worth of convertible bonds are exercised and converted into shares based on the conversion price of EUR 0.0175 (95% of 30-days VWAP on 30 May 2024).

### About BioSenic

BioSenic is a leading biotech company specializing in the development of clinical assets issued from its Medsenic's arsenic trioxide (ATO) platform. Key target indications for the autoimmune platform include graft-versus-host-disease (GvHD), systemic lupus erythematosus (SLE), and now systemic sclerosis (SSc).

Following the merger in October 2022, BioSenic combined the strategic positionings and strengths of Medsenic and Bone Therapeutics. The merger specifically enables Medsenic/Biosenic to develop an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/oral ATO (OATO).

BioSenic is based in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert, Belgium. Further information is available at <http://www.biosenic.com>.

### About the main Medsenic/BioSenic technology platform

The **ATO platform** provides derived active products with immunomodulatory properties and fundamental effects on the activated cells of the immune system. One direct application is its use in onco-immunology to treat GvHD (Graft-versus-Host Disease) in its chronic, established stage. cGvHD is one of the most common and clinically significant complications affecting long-term survival of allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Medsenic has been successful in a phase 2 trial with its intravenous formulation, **Arcscimed®**, which has orphan drug designation status by FDA and EMA. The company is heading towards an international phase 3 confirmatory study, with its new, IP-protected, OATO formulation. Another selected target is moderate-to-severe forms of systemic lupus erythematosus (SLE), using the same oral formulation. ATO has shown good safety and significant clinical efficacy on several affected organs (skin, mucosae, and the gastrointestinal tract). Systemic sclerosis is now full part of the clinical pipeline of Medsenic/BioSenic. This serious chronic disease badly affects skin, lungs, or vascularization, and has no current effective treatment. Preclinical studies on pertinent animal models are positive, giving good grounds to launch a phase 2 clinical protocol, using new immunomodulatory formulations of APIs recognized to be active on the immune system.

The company is currently focusing its present R&D and clinical activities on a selective, accelerated development of its autoimmune platform.

Note: The allogeneic cell therapy platform-originating from the previous listed company Bone Therapeutics company, may be of renewed interest by using isolated and purified differentiated bone marrow Mesenchymal Stromal Cells (MSCs) as a starting material for further isolation of passive or active biological subcellular elements. Indeed, these cells may provide new subcellular vesicles potentially able to deliver a unique and proprietary approach to organ repair. BioSenic is now involved in determining new patentable approaches in this complex area of cell therapy.

### For further information, please contact:

**BioSenic SA**

François Rieger, PhD, CEO

Tel: +33 (0)671 73 31 59

investorrelations@biosenic.com

---

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the company or, as appropriate, the company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

---